CoChat

Ablation of Tumor Necrosis Factor Is Associated with Decreased Inflammation and Alterations of the Microbiota in a Mouse Model of Inflammatory Bowel Disease

Open access
Jones-Hall, Yava L., Kozik, Ariangela, Nakatsu, Cindy · 2015 · PLOS ONE
Cited by 81

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Inflammatory bowel disease (IBD) is associated with prolonged, excess secretions of Tumor Necrosis Factor (TNF). Many patients with IBD have successful management of IBD symptoms by blocking TNF secretion or signaling. However, some patients are non-responsive to this therapy, eventually become refractory to therapy, or may develop harmful side-effects [corrected]. Alterations in the microbiota that are associated with the lack of TNF could be a contributing cause of this therapeutic insufficiency seen in some patients. Here we use wildtype (WT) and mice lacking Tnf (Tnf-/-) in an acute TNBS colitis model to investigate the role of TNF in colitis and how its presence or absence affects the colonic microbiota. As expected, Tnf-/- had less severe inflammation than WT mice. Microbiome analysis revealed significant Tnf dependent-differences in alpha and beta diversity. There were also notable differences in many species that were also primarily Tnf dependent. Taken together, our data indicates that TNF contributes significantly to the inflammation and microbiotal alterations in that occur in IBD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0119441

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 51

  1. B Khor, 2011, Genetics and pathogenesis of inflammatory bowel disease, Nature, 474, 307, 10.1038/nature10209 · DOI · Paper page
  2. RS Blumberg, 2009, Inflammation in the intestinal tract: pathogenesis and treatment, Dig Dis, 27, 455, 10.1159/000235851 · DOI
  3. DK Podolsky, 2002, Inflammatory bowel disease, N Engl J Med, 347, 417, 10.1056/NEJMra020831 · DOI · Paper page
  4. K Matsuo, 1997, Histochemistry of the surface mucous gel layer of the human colon, Gut, 40, 782, 10.1136/gut.40.6.782 · DOI · Paper page
  5. YH Sheng, 2012, Mucins in inflammatory bowel diseases and colorectal cancer, J Gastroenterol Hepatol, 27, 28, 10.1111/j.1440-1746.2011.06909.x · DOI · Paper page
  6. LW Peterson, 2014, Intestinal epithelial cells: regulators of barrier function and immune homeostasis, Nat Rev Immunol, 14, 141, 10.1038/nri3608 · DOI · Paper page
  7. S Ardizzone, 2005, Biologic therapy for inflammatory bowel disease, Drugs, 65, 2253, 10.2165/00003495-200565160-00002 · DOI · Paper page
  8. ZJ Liu, 2009, Potential role of Th17 cells in the pathogenesis of inflammatory bowel disease, World J Gastroenterol, 15, 5784, 10.3748/wjg.15.5784 · DOI · Paper page
  9. I Monteleone, 2009, Interleukin-23 and Th17 cells in the control of gut inflammation, Mediators Inflamm, 2009, 297645, 10.1155/2009/297645 · DOI · Paper page
  10. MF Neurath, 2014, New targets for mucosal healing and therapy in inflammatory bowel diseases, Mucosal Immunol, 7, 6, 10.1038/mi.2013.73 · DOI · Paper page
  11. K Li, 2012, Analyses of the microbial diversity across the human microbiome, PLoS ONE, 7, e32118, 10.1371/journal.pone.0032118 · DOI · Paper page
  12. FD Bushman, 2013, Diet, the human gut microbiota, and IBD, Anaerobe, 30, 00052
  13. V Leone, 2013, Diet, microbes, and host genetics: the perfect storm in inflammatory bowel diseases, J Gastroenterol, 48, 315, 10.1007/s00535-013-0777-2 · DOI · Paper page
  14. J Bien, 2013, The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease?, Therap Adv Gastroenterol, 6, 53, 10.1177/1756283X12454590 · DOI · Paper page
  15. S Sha, 2013, The biodiversity and composition of the dominant fecal microbiota in patients with inflammatory bowel disease, Diagn Microbiol Infect Dis, 75, 245, 10.1016/j.diagmicrobio.2012.11.022 · DOI · Paper page
  16. S Oliva, 2012, Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis, Aliment Pharmacol Ther, 35, 327, 10.1111/j.1365-2036.2011.04939.x · DOI · Paper page
  17. E Papa, 2012, Non-invasive mapping of the gastrointestinal microbiota identifies children with inflammatory bowel disease, PLoS ONE, 7, e39242, 10.1371/journal.pone.0039242 · DOI · Paper page
  18. CP Braegger, 1992, Tumour necrosis factor alpha in stool as a marker of intestinal inflammation, Lancet, 339, 89, 10.1016/0140-6736(92)90999-J · DOI · Paper page
  19. H Masuda, 1995, Expression of IL-8, TNF-alpha and IFN-gamma m-RNA in ulcerative colitis, particularly in patients with inactive phase, J Clin Lab Immunol, 46, 111
  20. SJ van Deventer, 1997, Review article: Chemokine production by intestinal epithelial cells: a therapeutic target in inflammatory bowel disease?, Aliment Pharmacol Ther, 3, 116, 10.1111/j.1365-2036.1997.tb00816.x · doi:10.1111/j.1365-2036.1997.tb00816.x
  21. C Thukral, 2005, The Role of Antibiotics in Inflammatory Bowel Disease, Curr Treat Options Gastroenterol, 8, 223, 10.1007/s11938-005-0014-z · DOI
  22. BG Feagan, 2001, Infliximab for the treatment of Crohn#x2019;s disease: efficacy, safety and pharmacoeconomics, Can J Clin Pharmacol, 8, 188
  23. JR Curtis, 2007, Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists, Arthritis Rheum, 56, 1125, 10.1002/art.22504 · DOI · Paper page
  24. JF Colombel, 2004, The safety profile of infliximab in patients with Crohn#x2019;s disease: the Mayo clinic experience in 500 patients, Gastroenterology, 126, 19, 10.1053/j.gastro.2003.10.047 · DOI · Paper page
  25. VV Jain, 2006, Reactivation histoplasmosis after treatment with anti-tumor necrosis factor alpha in a patient from a nonendemic area, Respir Med, 100, 1291, 10.1016/j.rmed.2005.09.020 · doi:10.1016/j.rmed.2005.09.020
  26. KL Wood, 2003, Histoplasmosis after treatment with anti-tumor necrosis factor—alpha therapy, Am J Respir Crit Care Med, 167, 1279, 10.1164/rccm.200206-563OC · DOI · Paper page
  27. C Abreu, 2013, Tuberculosis in anti-TNF-alpha treated patients remains a problem in countries with an intermediate incidence: Analysis of 25 patients matched with a control population, J Crohns Colitis, 10, 00108
  28. M Neurath, 2000, TNBS-colitis, Int Rev Immunol, 19, 51, 10.3109/08830180009048389 · DOI · Paper page
  29. W Strober, 2002, The immunology of mucosal models of inflammation, Annu Rev Immunol, 20, 495, 10.1146/annurev.immunol.20.100301.064816 · DOI · Paper page
  30. M Pasparakis, 1996, Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response, J Exp Med, 184, 1397, 10.1084/jem.184.4.1397 · DOI · Paper page
  31. Y Naito, 2003, Enhanced intestinal inflammation induced by dextran sulfate sodium in tumor necrosis factor—alpha deficient mice, J Gastroenterol Hepatol, 18, 560, 10.1046/j.1440-1746.2003.03034.x · DOI · Paper page
  32. ZZ Liu, 2008, Accurate taxonomy assignments from 16S rRNA sequences produced by highly parallel pyrosequencers, Nucleic Acids Res, 36, e120, 10.1093/nar/gkn491 · DOI · Paper page
  33. CW Nossa, 2010, Design of 16S rRNA gene primers for 454 pyrosequencing of the human foregut microbiome, World J Gastroenterol, 16, 4135, 10.3748/wjg.v16.i33.4135 · DOI · Paper page
  34. JG Caporaso, 2010, QIIME allows analysis of high-throughput community sequencing data, Nat Meth, 7, 335, 10.1038/nmeth.f.303 · DOI · Paper page
  35. D McDonald, 2012, An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea, ISME J, 6, 610, 10.1038/ismej.2011.139 · DOI · Paper page
  36. M Hamady, 2010, Fast UniFrac: facilitating high-throughput phylogenetic analyses of microbial communities including analysis of pyrosequencing and PhyloChip data, ISME J, 4, 17, 10.1038/ismej.2009.97 · DOI · Paper page
  37. M Anderson, 2001, A new method for non-parametric multivariate analysis of variance, Austral Ecology, 26, 32
  38. CJF ter Braak, 1986, Canonical correspondence analysis: A new eigenvector technique for multivariate direct gradient analysis, Ecology, 67, 1167, 10.2307/1938672 · DOI · Paper page
  39. H Tuomisto, 2010, A diversity of beta diversities: straightening up a concept gone awry. Part 1. Defining beta diversity as a function of alpha and gamma diversity, Ecography, 33, 2, 10.1111/j.1600-0587.2009.05880.x · DOI · Paper page
  40. M Noti, 2010, TNF suppresses acute intestinal inflammation by inducing local glucocorticoid synthesis, J Exp Med, 207, 1057, 10.1084/jem.20090849 · DOI · Paper page
  41. MF Neurath, 1997, Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice, Eur J Immunol, 27, 1743, 10.1002/eji.1830270722 · DOI · Paper page
  42. C Shen, 2007, Remission-inducing effect of anti-TNF monoclonal antibody in TNBS colitis: Mechanisms beyond neutralization?, Inflamm Bowel Dis, 13, 308, 10.1002/ibd.20005 · DOI
  43. W Fries, 2008, Infliximab and etanercept are equally effective in reducing enterocyte apoptosis in experimental colitis, Int J Med Sci, 5, 169, 10.7150/ijms.5.169 · DOI
  44. S Zeissig, 2004, Downregulation of epithelial apoptosis and barrier repair in active Crohn#x2019;s disease by tumour necrosis factor alpha antibody treatment, Gut, 53, 1295, 10.1136/gut.2003.036632 · DOI · Paper page
  45. W Qiu, 2011, PUMA-mediated intestinal epithelial apoptosis contributes to ulcerative colitis in humans and mice, J Clin Invest, 121, 1722, 10.1172/JCI42917 · DOI · Paper page
  46. M Iizuka, 2011, Wound healing of intestinal epithelial cells, World J Gastroenterol, 17, 2161, 10.3748/wjg.v17.i17.2161 · DOI · Paper page
  47. MG Rooks, 2014, Gut microbiome composition and function in experimental colitis during active disease and treatment-induced remission, ISME J, 8, 1403, 10.1038/ismej.2014.3 · DOI · Paper page
  48. LL Presley, 2010, Bacteria associated with immunoregulatory cells in mice, Appl Environ Microbiol, 76, 936, 10.1128/AEM.01561-09 · DOI · Paper page
  49. PP Bosshard, 2002, Turicibacter sanguinis gen. nov., sp. nov., a novel anaerobic, Gram-positive bacterium, Int J Syst Evol Microbiol, 52, 1263, 10.1099/00207713-52-4-1263 · DOI · Paper page
  50. MG Rooks, 2014, Gut microbiome composition and function in experimental colitis during active disease and treatment-induced remission, ISME J, 8, 1403, 10.1038/ismej.2014.3 · DOI · Paper page
  51. J Sarowska, 2013, The therapeutic effect of probiotic bacteria on gastrointestinal diseases, Adv Clin Exp Med, 22, 759

Cited by

See all 81

Metadata

Authors
Jones-Hall, Y. L., Kozik, A., & Nakatsu, C.
Venue
PLOS ONE
Published
2015-03-16
Volume
10
Issue
3
Pages
e0119441
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2091256633
Cited by
81
References
15
FWCI
4.73
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ablation of Tumor Necrosis Factor Is Associated with Decreased Inflammation and Alterations of the Microbiota in a Mouse Model of Inflammatory Bowel Disease. https://app.cochat.ai/papers/10.1371/journal.pone.0119441
The paper
Jones-Hall, Y. L., Kozik, A., & Nakatsu, C. (2015). Ablation of Tumor Necrosis Factor Is Associated with Decreased Inflammation and Alterations of the Microbiota in a Mouse Model of Inflammatory Bowel Disease. PLOS ONE. https://doi.org/10.1371/journal.pone.0119441

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.